nido-Dicarbaborate Induces Potent and Selective Inhibition of Cyclooxygenase-2
- Univ. Leipzig (Germany)
- Vanderbilt Univ., Nashville, TN (United States)
- Univ. Leipzig (Germany); Rheinische Friedrich-Wilhelms-Univ. Bonn (Germany)
- Cornell Univ., Ithaca, NY (United States); Argonne National Lab. (ANL), Argonne, IL (United States)
Carbaboranes are increasingly studied as pharmacophores, particularly as replacements for aromatic systems. However, especially ortho–carbaborane is prone to degradation of the cluster, which hampers biological application. This study demonstrates that deboronation of the cluster may not only lead to a more active analogue, but can also improve the solubility and stability of a carbaborane–containing inhibitor. Notably, introduction of a nido–dicarbaborate cluster into the cyclooxygenase (COX) inhibitor indomethacin results in remarkably increased inhibitory potency and selectivity for COX–2 relative to the respective phenyl analogue. The first crystal structure of a carbaborane–containing inhibitor bound to COX–2 further reveals a novel binding mode for the inhibitor that is strikingly different from that of indomethacin. Furthermore, these results indicate that nido–dicarbaborate is a promising pharmacophore that exhibits properties which are also highly beneficial for its introduction into other inhibitor classes.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC); National Institutes of Health (NIH); National Inst. of General Medical Sciences
- Grant/Contract Number:
- AC02‐06CH11357; CA89450; P41 GM103403
- OSTI ID:
- 1236266
- Journal Information:
- ChemMedChem, Vol. 11, Issue 2; ISSN 1860-7179
- Publisher:
- ChemPubSoc EuropeCopyright Statement
- Country of Publication:
- United States
- Language:
- ENGLISH
Web of Science
Similar Records
Dual cyclooxygenase–fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site
Structural Basis of Enantioselective Inhibition of Cyclooxygenase-1 by S-[alpha]-Substituted Indomethacin Ethanolamides